News
The promising trial results may be a breakthrough for cisplatin-ineligible patients with muscle-invasive bladder cancer.
In the EV-303/KEYNOTE-905 study, the combination of nectin-4-directed antibody-drug conjugate (ADC) Padcev (enfortumab ...
Keytruda and Padcev generated promising topline results for those with muscle-invasive bladder cancer who are ineligible for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback